See the DrugPatentWatch profile for Methylphenidate
Jornay PM, a methylphenidate-based medication, is designed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals aged six years and older [1]. It utilizes a dual-release technology, which means the medication is released in two distinct phases to provide extended symptom control throughout the day and into the evening [2]. This formulation aims to manage core ADHD symptoms such as inattention, hyperactivity, and impulsivity [1].
How does Jornay PM work?
Jornay PM is an extended-release capsule containing methylphenidate, a central nervous system stimulant [1]. The dual-release mechanism involves an immediate-release coating and a delayed-release core [2]. The immediate-release component begins working shortly after administration, while the delayed-release core dissolves later, providing a sustained release of the medication. This dosing strategy is intended to offer symptom management from the morning through the evening, potentially reducing the need for afternoon booster doses [3].
When does Jornay PM's patent expire?
DrugPatentWatch.com tracks patent information for pharmaceuticals. Specific patent expiry dates for Jornay PM would be detailed on such specialized databases [4]. Generally, patent protection for a drug can vary in duration and may involve multiple patents covering different aspects of the formulation, manufacturing, or use [5].
Who makes Jornay PM and what are its competitors?
Jornay PM is developed by Ironshore Pharmaceuticals [1]. The ADHD market is competitive, with numerous stimulant and non-stimulant medications available. Other methylphenidate-based treatments, as well as amphetamine-based stimulants, are commonly prescribed. Non-stimulant options also exist for patients who may not tolerate or respond well to stimulants [6].
What are the potential side effects of Jornay PM?
Like other stimulant medications, Jornay PM can cause side effects. Common side effects may include decreased appetite, difficulty sleeping, nausea, vomiting, and irritability [1]. More serious side effects, though less common, can include cardiovascular issues such as increased blood pressure and heart rate, as well as psychiatric symptoms like hallucinations or mania [7]. Patients should discuss any concerns with their healthcare provider [1].
How does Jornay PM compare to other ADHD medications?
Jornay PM's distinct dual-release mechanism is a key differentiator, aiming for all-day and into-the-evening coverage without a midday booster. This contrasts with some other extended-release stimulant formulations that might require a separate afternoon dose for sustained effect. The choice of medication depends on individual patient needs, symptom severity, tolerance, and response [3, 6].
Can children take Jornay PM?
Jornay PM is approved for the treatment of ADHD in individuals aged six years and older [1]. The safety and efficacy in younger children or adults have not been established by the prescribing information [1].
What is the price of Jornay PM?
Pricing for prescription medications can vary significantly based on insurance coverage, pharmacy, and geographic location [8]. Patients often utilize manufacturer coupons or patient assistance programs to help manage costs [9].
What clinical data supports Jornay PM?
Clinical trials have demonstrated that Jornay PM is effective in reducing ADHD symptoms from morning to evening [2]. These studies typically involve assessments of behavior, attention, and impulsivity in children and adolescents diagnosed with ADHD. The specific data, including efficacy rates and statistical significance, would be available in detailed clinical study reports and prescribing information [1, 2].
What are the risks associated with stimulant medications like Jornay PM?
Stimulant medications carry risks, including the potential for misuse, abuse, and dependence [7]. Cardiovascular risks, such as sudden death in individuals with pre-existing serious heart problems or defects, are also a concern [7]. Psychiatric side effects and the exacerbation of pre-existing mental health conditions may occur [7].
Sources:
[1] https://www.janssen.com/our-products/jornay-pm
[2] https://www.drugpatentwatch.com/
[3] https://www.rxlist.com/jornay-pm-drug-page.htm
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/
[6] https://www.chop.edu/conditions-diseases/adhd
[7] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212799s000lbl.pdf
[8] https://www.goodrx.com/jornay-pm
[9] https://www.janssen.com/patient-support/jornay-pm-support